Abstract
Purpose: While next generation sequencing enables comprehensive, unbiased, and absolute quantification of molecules in a biological sample, the way in which sequencing studies are designed, executed, and analyzed can dramatically impact the results. Among the promising applications of sequencing is biomarker discovery. Since there are currently no validated biomarkers for osteoarthritis (OA), sequencing represents a viable strategy for identifying new biomarkers in different disease stages. In particular, microRNAs (short noncoding RNA sequences) are excellent biomarker candidates because they are stable, easy to detect in circulation, and reflective of disease activity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
